Upcoming Phase 2 Data Expected For Longeverons (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimers Sector What To Look For
–News Direct–
By David Willey, Benzinga
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B cellular drug in the next 3 to 4 months.
Longeverons primary drug candidate, a cell-based medicine, is being tested for several indications, including Aging-related Frailty, a rare pediatric disease called hypoplastic left heart syndrome (HLHS), and Alzheimers disease (AD). It is running phase 2 trials for each of these conditions and expects to announce top-line results for the AD trial soon.
A previous clinical study indicated that Lomecel-Bs mechanisms of action (MoA) had the potential to affect multiple AD markers simultaneously, such as reducing neuroinfl...